— Know what they know.
Not Investment Advice

DFTX NASDAQ

Definium Therapeutics, Inc.
1W: +3.4% 1M: -3.9% 3M: -15.6% YTD: +174.2%
$37.40
-0.20 (-0.53%)
 
Weekly Expected Move ±7.4%
$32 $35 $37 $40 $43
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 31 · $5.0B mcap · 129M float · 2.15% daily turnover · Short 50% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
35.2 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: 82.4%
Cost Advantage
33
Intangibles
25
Switching Cost
60
Network Effect
22
Scale
27
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. DFTX has No discernible competitive edge (35.2/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. ROIC of 82.4% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$55
Low
$70
Avg Target
$79
High
Based on 10 analysts since Aug 6, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 12Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$69.15
Analysts13
Consensus Change History
DateFieldFromTo
2026-01-24 _new_coverage None ADDED
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-09-15 Canaccord Genuity — $64 $78 +14 +93.8% $40.25
2026-09-15 UBS — Initiated $70 — +73.9% $40.25
2026-09-15 Robert W. Baird — $75 $79 +4 +96.3% $40.25
2026-09-14 Oppenheimer — $70 $75 +5 +86.3% $40.25
2026-08-14 Maxim Group — Initiated $55 — +28.3% $42.88
2026-08-13 Canaccord Genuity Sumant Kulkarni $58 $64 +6 +49.6% $42.79
2026-08-13 Robert W. Baird — $37 $75 +38 +75.3% $42.79
2026-08-12 RBC Capital — $36 $66 +30 +54.2% $42.79
2026-08-12 Needham — $50 $66 +16 +54.2% $42.79
2026-08-12 Oppenheimer — $60 $70 +10 +62.6% $43.05
2026-07-27 Wells Fargo Benjamin Burnett Initiated $68 — +57.5% $43.17
2026-07-24 Piper Sandler — $48 $73 +25 +70.0% $42.93
2026-07-08 Stifel Nicolaus — $30 $60 +30 +34.9% $44.48
2026-06-30 Canaccord Genuity — $60 $58 -2 +24.6% $46.55
2026-06-23 Needham Ami Fadia $28 $50 +22 +36.4% $36.67
2026-06-22 Canaccord Genuity — $38 $60 +22 +57.4% $38.11
2026-06-22 Oppenheimer — $40 $60 +20 +58.1% $37.95
2026-06-22 Leerink Partners Marc Goodman Initiated $52 — +37.2% $37.91
2026-05-08 Piper Sandler David Amsellem $49 $48 -1 +106.9% $23.20
2026-04-23 Oppenheimer — $20 $40 +20 +74.5% $22.93
2026-04-16 Stifel Nicolaus Paul Matteis Initiated $30 — +33.6% $22.46
2026-04-16 Canaccord Genuity Sumant Kulkarni $14 $38 +24 +71.6% $22.15
2026-04-10 Piper Sandler — Initiated $49 — +127.4% $21.55
2026-02-23 Wolfe Research — Initiated $25 — +47.5% $16.95
2026-01-29 Jefferies — Initiated $30 — +74.0% $17.24
2026-01-29 Robert W. Baird — $16 $37 +21 +119.7% $16.84
2026-01-23 RBC Capital — $22 $36 +14 +106.9% $17.40
2025-10-13 Needham Ami Fadia Initiated $28 — +137.1% $11.81
2025-03-07 Robert W. Baird — Initiated $16 — +134.3% $6.83
2024-09-16 Canaccord Genuity Sumart Kulkami Initiated $14 — +117.1% $6.45
2024-06-05 RBC Capital Brian Abrahams $5 $22 +17 +166.7% $8.25
2024-05-13 Oppenheimer Francois Brisebois Initiated $20 — +132.4% $8.61
2022-11-16 RBC Capital — Initiated $5 — +74.8% $2.86

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
Oct 02, 2026
DCF
3
ROE
1
ROA
1
D/E
2
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. DFTX receives an overall rating of C. Areas of concern: ROE (1/5), ROA (1/5), D/E (2/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-08-14 C+ C
2026-08-10 C- C+
2026-02-04 None ADDED

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ — Grade A+
Profitability
—
Balance Sheet
0
Earnings Quality
45
Growth
—
Value
34
Momentum
—
Safety
100
Cash Flow
—

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
15.37
Safe Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✗ ✗ ✓ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
-8.01
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
BBB+
Score: 64.7/100
Earnings Quality
—
OCF/NI: 0.40x
Accruals: -12.6%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. DFTX scores 15.37, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. DFTX scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. DFTX's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. DFTX receives an estimated rating of BBB+ (score: 64.7/100).

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-10.87x
PEG
0.15x
P/S
0.00x
P/B
4.51x
P/FCF
-54.57x
P/OCF
—
EV/EBITDA
-17.85x
EV/Revenue
—
EV/EBIT
-17.80x
EV/FCF
-43.59x
Earnings Yield
-4.53%
FCF Yield
-1.83%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. DFTX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
1.011
EBT / EBIT
×
EBIT Margin
—
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.211
Assets / Equity
=
ROE
-25.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. DFTX's ROE of -25.7% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 189 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$37.40
Median 1Y
$109.90
5th Pctile
$32.16
95th Pctile
$383.70
Ann. Volatility
74.6%
Analyst Target
$69.15
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Robert Barrow
Chief Executive Officer
$655,000 $11,719,750 $12,767,442
Brandi L. Roberts
Chief Financial Officer
$288,750 $1,815,000 $5,116,362
Daniel Karlin, M.D.
Chief Medical Officer
$510,000 $3,262,525 $4,001,258

CEO Pay Ratio

28:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $12,767,442
Avg Employee Cost (SGA/emp): $463,276
Employees: 105

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
105
+41.9% YoY
Revenue / Employee
—
Profit / Employee
$-1,750,410
NI: $-183,793,000
SGA / Employee
$463,276
Avg labor cost proxy
R&D / Employee
$1,120,619
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q1'26 Q2'26 Current
ROE -27.6% -25.7% -25.70%
ROA -19.2% -21.2% -21.21%
ROIC 49.5% 82.4% 82.41%
ROCE -23.7% -24.4% -24.44%
Gross Margin — — —
Operating Margin — — —
Net Margin — — —
EBITDA Margin — — —
FCF Margin — — —
OCF Margin — — —
ROIC Economic snapshot only -11.11%
Cash ROA snapshot only -8.57%
Valuation
Metric Trend Q1'26 Q2'26 Current
P/E Ratio -26.67 -22.05 -10.872
P/S Ratio — — 0.000
P/B Ratio 7.37 5.67 4.506
P/FCF -48.23 -54.57 -54.571
P/OCF — — —
EV/EBITDA -22.37 -17.85 -17.853
EV/Revenue — — —
EV/EBIT -22.18 -17.80 -17.804
EV/FCF -39.47 -43.59 -43.593
Earnings Yield -3.7% -4.5% -4.53%
FCF Yield -2.1% -1.8% -1.83%
PEG Ratio snapshot only 0.147
Price/Tangible Book snapshot only 5.793
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q1'26 Q2'26 Current
Current Ratio 4.69 6.95 6.947
Quick Ratio 4.69 6.95 6.947
Debt/Equity 0.00 0.04 0.040
Net Debt/Equity -1.34 -1.14 -1.140
Debt/Assets 0.00 0.03 0.033
Debt/EBITDA -0.00 -0.16 -0.157
Net Debt/EBITDA 4.96 4.50 4.496
Interest Coverage -60.93 -94.27 -94.272
Equity Multiplier 1.44 1.21 1.211
Cash Ratio snapshot only 6.895
Debt Service Coverage snapshot only -94.017
Cash to Debt snapshot only 29.722
FCF to Debt snapshot only -2.616
Defensive Interval snapshot only 2945.8 days
Efficiency & Turnover
Metric Trend Q1'26 Q2'26 Current
Asset Turnover 0.00 0.00 0.000
Inventory Turnover — — —
Receivables Turnover — — —
Payables Turnover 0.00 0.00 —
DSO — — —
DIO — — —
DPO — — —
Cash Conversion Cycle — — —
Cash Velocity snapshot only 0.000
Growth Quality
Metric Trend Q1'26 Q2'26 Current
Revenue Stability — — —
Earnings Stability — — —
Margin Stability — — —
Rev. Growth Consistency 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.000
FCF Positive Streak 0 0 0
Earnings Persistence — — —
Earnings Smoothness — — —
ROE Trend — — —
Gross Margin Trend — — —
FCF Margin Trend — — —
Sustainable Growth Rate — — —
Internal Growth Rate — — —
Cash Flow Quality
Metric Trend Q1'26 Q2'26 Current
OCF/Net Income 0.55 0.40 0.404
FCF/OCF 1.00 1.00 1.000
FCF/Net Income snapshot only 0.404
CapEx/Revenue — — —
CapEx/Depreciation snapshot only 0.000
Accruals Ratio -0.09 -0.13 -0.126
Sloan Accruals snapshot only -0.134
Dividends & Buybacks
Metric Trend Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00
Payout Ratio — — —
FCF Payout Ratio — — —
Total Payout Ratio — — —
Div. Increase Streak — — —
Chowder Number — — —
Buyback Yield 0.0% 0.0% 0.00%
Net Buyback Yield -0.3% -15.6% -15.63%
Total Shareholder Return -0.3% -15.6% -15.63%
DuPont Factors
Metric Trend Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.02 1.01 1.011
EBIT Margin — — —
Asset Turnover 0.00 0.00 0.000
Equity Multiplier 1.44 1.21 1.211
Per Share
Metric Trend Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.71 $-2.13 $-2.13
Book Value/Share $2.56 $8.30 $8.30
Tangible Book/Share $2.38 $8.12 $8.12
Revenue/Share $0.00 $0.00 $0.00
FCF/Share $-0.39 $-0.86 $-1.51
OCF/Share $-0.39 $-0.86 $-1.51
Cash/Share $3.43 $9.79 $9.79
EBITDA/Share $-0.69 $-2.10 $-2.10
Debt/Share $0.00 $0.33 $0.33
Net Debt/Share $-3.43 $-9.46 $-9.46
Academic Models
Metric Trend Q1'26 Q2'26 Current
Altman Z-Score — — 15.370
Altman Z-Prime snapshot only 29.850
Piotroski F-Score 2 2 2
Beneish M-Score — — —
Ohlson O-Score snapshot only -8.013
ROIC (Greenblatt) snapshot only -24.99%
Net-Net WC snapshot only $8.11
Credit
Metric Trend Q1'26 Q2'26 Current
Credit Rating snapshot only BBB+
Credit Score 70.23 64.66 64.662
Credit Grade snapshot only 8
Implied Spread (bps) snapshot only 225.000
Industry Credit Rank snapshot only 62
Sector Credit Rank snapshot only 58

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms